Literature DB >> 35020816

GLP-1 Receptor Agonists for Cardiovascular Protection: A Matter of Time.

Irene Caruso, Angelo Cignarelli, Luigi Laviola, Francesco Giorgino.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35020816      PMCID： PMC8914435          DOI： 10.2337/dc21-1839

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  5 in total

Review 1.  Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials.

Authors:  Irene Caruso; Angelo Cignarelli; Francesco Giorgino
Journal:  Trends Endocrinol Metab       Date:  2019-08-07       Impact factor: 12.015

2.  Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.

Authors:  Hertzel C Gerstein; Naveed Sattar; Julio Rosenstock; Chinthanie Ramasundarahettige; Richard Pratley; Renato D Lopes; Carolyn S P Lam; Nardev S Khurmi; Laura Heenan; Stefano Del Prato; Leanne Dyal; Kelley Branch
Journal:  N Engl J Med       Date:  2021-06-28       Impact factor: 91.245

3.  Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.

Authors:  William T Cefalu; Sanjay Kaul; Hertzel C Gerstein; Rury R Holman; Bernard Zinman; Jay S Skyler; Jennifer B Green; John B Buse; Silvio E Inzucchi; Lawrence A Leiter; Itamar Raz; Julio Rosenstock; Matthew C Riddle
Journal:  Diabetes Care       Date:  2018-01       Impact factor: 19.112

4.  Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study.

Authors:  Marcus Hompesch; Jahoon Kang; OakPil Han; Michael E Trautmann; Christopher H Sorli; Ike Ogbaa; John Stewart; Linda Morrow
Journal:  BMJ Open Diabetes Res Care       Date:  2021-06

5.  Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes.

Authors:  Kun-Ho Yoon; Jahoon Kang; Se Chang Kwon; Michael E Trautmann; Marcus Hompesch; John Stewart; Christopher H Sorli
Journal:  Diabetes Obes Metab       Date:  2020-04-04       Impact factor: 6.577
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.